4.6 Article

Involvement of NINJ2 Protein in Inflammation and Blood-Brain Barrier Transmigration of Monocytes in Multiple Sclerosis

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Endocrinology & Metabolism

Association between genetic variants and risk of obsessive-compulsive disorder

Mohammad Taheri et al.

Summary: The study genotyped six SNPs within MOCOS, NINJ2, and AKT1 genes in a cohort of Iranian patients with OCD. rs1057251 and rs3809263 were found to be associated with an increased risk of OCD in the Iranian population. Other SNPs were not found to be associated with OCD risk in any inheritance model.

METABOLIC BRAIN DISEASE (2022)

Article Neurosciences

Interdependency of NINJ2 gene expression and polymorphism with susceptibility and response to interferon beta in patients with multiple sclerosis

Mehdi Khorrami et al.

Summary: This study found that the NINJ2 gene expression level and rs7298096 genotype may affect the response to IFN-β in patients with RRMS.

INTERNATIONAL JOURNAL OF NEUROSCIENCE (2022)

Article Immunology

Spinal Ninjurin2 contributes to the neuropathic pain via NF-κB-mediated neuroinflammation in the spared sciatic nerve injury rats

Hai-Ming Guo et al.

Summary: NINJ2 is involved in the development of nerve injury-induced neuropathic pain by activating neuroinflammation in the spinal cord via the NF-Kappa B pathway. The study suggests that reducing NINJ2 levels can partially block the development of pain in SNI rats.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Article Clinical Neurology

A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis

Silvia Peroni et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Article Clinical Neurology

NINJ2 Gene Polymorphisms and Susceptibility to Ischemic An Updated Meta-Analysis

Fangfang Nie et al.

CURRENT NEUROVASCULAR RESEARCH (2019)

Article Cell Biology

Ninjurin2 overexpression promotes glioma cell growth

Li-Na Zhou et al.

AGING-US (2019)

Article Clinical Neurology

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Alan J. Thompson et al.

LANCET NEUROLOGY (2018)

Correction Medicine, General & Internal

Multiple sclerosis (vol 4, 43, 2018)

Massimo Filippi et al.

NATURE REVIEWS DISEASE PRIMERS (2018)

Article Genetics & Heredity

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis

F. Clarelli et al.

PHARMACOGENOMICS JOURNAL (2017)

Article Cell Biology

NINJ2- A novel regulator of endothelial inflammation and activation

Jingjing Wang et al.

CELLULAR SIGNALLING (2017)

Review Cardiac & Cardiovascular Systems

Monocyte trafficking across the vessel wall

Teresa Gerhardt et al.

CARDIOVASCULAR RESEARCH (2015)

Review Immunology

Immunopathology of multiple sclerosis

Calliope A. Dendrou et al.

NATURE REVIEWS IMMUNOLOGY (2015)

Review Immunology

Revised diagnostic criteria of multiple sclerosis

Ron Milo et al.

AUTOIMMUNITY REVIEWS (2014)

Article Biochemistry & Molecular Biology

Ninjurin1 Deficiency Attenuates Susceptibility of Experimental Autoimmune Encephalomyelitis in Mice

Bum Ju Ahn et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2014)

Review Neurosciences

The hCMEC/D3 cell line as a model of the human blood brain barrier

Babette Weksler et al.

FLUIDS AND BARRIERS OF THE CNS (2013)

Article Biochemical Research Methods

NIH Image to ImageJ: 25 years of image analysis

Caroline A. Schneider et al.

NATURE METHODS (2012)

Article Clinical Neurology

NINJ2 polymorphism is associated with ischemic stroke in Chinese Han population

Xin-hong Wan et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)

Review Clinical Neurology

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

Jerold Chun et al.

CLINICAL NEUROPHARMACOLOGY (2010)

Article Medicine, General & Internal

Genomewide Association Studies of Stroke

M. Arfan Ikram et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Review Immunology

Integrin modulation and signaling in leukocyte adhesion and migration

David M. Rose et al.

IMMUNOLOGICAL REVIEWS (2007)

Article Medicine, General & Internal

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

CH Polman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)